ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

sintilimab

Also written as “Sintilimab”, “IBI308” and “IBI939+ Sintilimab”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Carcinoma, Hepatocellular · Stomach Neoplasms · Colorectal Neoplasms · Esophageal Squamous Cell Carcinoma, led by 10 companies.

Drug pageSintilimab: every studyMany companies study it; this page follows only the 40 they lead. All 403 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since May 7, 201740 company-led studies, 13 open or runningNext primary completion: Dec 31, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Innovent Biologics295 open or runningphase 3since May 7, 2017Oct 8, 2016Mar 25, 2030phase 3 · NCT07917468
HUTCHMEDits history only31 open or runningphase 3since Aug 16, 2022Mar 27, 2019Jan 8, 2029phase 3 · NCT06584032
Beijing Aosaikang Pharmaceuticalits history only11 open or runningphase 2since Nov 21, 2022Nov 21, 2022none ahead
Chipscreen Biosciencesits history only11 open or runningphase 3since Jun 28, 2024Jun 28, 2024May 31, 2028phase 3 · NCT06497985
CSPC Pharmaceutical Groupits history only11 open or runningphase 2since Jul 30, 2026Jul 30, 2026Sep 30, 2029phase 2 · NCT07761286
Sichuan Luzhou Buchang Biopharmaceuticalits history only11 open or runningphase 1since Jan 2, 2025Jan 2, 2025none ahead
Simcere Pharmaceutical Groupits history only10 open or runningphase 1since Jan 29, 2023Jan 29, 2023none ahead
Suzhou Zelgen Biopharmaceuticalsits history only11 open or runningphase 2since Aug 14, 2024Aug 14, 2024none ahead
TaiRxits history only11 open or runningphase 2since Mar 31, 2026Mar 31, 2026Dec 31, 2027phase 2 · NCT07521852
TJ Biopharmaits history only11 open or runningphase 2since May 21, 2025May 21, 2025none ahead

Also a collaborator on its studies: Fortrea.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Innovent Biologics only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Not listed one by one: 15 earlier studies, Oct 8, 2016 to Feb 18, 2020.

  1. Jun 9, 2018Named sintilimabINNProposed as its International Nonproprietary Name in WHO's List 119 · before, IBI308
  2. Apr 17, 2020Phase 1 study in Advanced MalignanciesNCT04353830 · 34 enrolled · China
  3. May 6, 2020Phase 1 study in Advanced Hepatocellular CarcinomaNCT04401813 · 97 enrolled · China
  4. Jun 9, 2020Phase 1 study in Advanced or Metastatic Solid TumorsNCT04427774 · 8 enrolled · China
  5. Dec 3, 2020Phase 3 study in Gastric AdenocarcinomaNCT04675983 · 36 enrolled · China
  6. Sep 1, 2021Phase 1 study in DLBCLNCT05039658 · 50 enrolled · China
  7. Oct 26, 2021Phase 3 study in Carcinoma, Non-Small-Cell LungNCT05116462 · 506 enrolled · China
  8. Nov 3, 2021Phase 1 study in Solid TumorNCT05119998 · 48 enrolled · China
  9. Mar 6, 2022Phase 2 study in Lymphoma, Large B-Cell, DiffuseNCT05280626 · 100 planned
  10. Mar 22, 2022Phase 1 study in Healthy Male SubjectsNCT05337267 · 117 enrolled · China
  11. Oct 5, 2022Phase 2 study in MelanomaNCT05572463 · United States, Australia, France and more
  12. Apr 17, 2023Phase 2 study in Non-squamous Non-small-cell Lung CancerNCT05849246 · 4 enrolled · China
  13. Mar 16, 2026Phase 2 study in CLDN18.2 PositiveNCT07483567 · 90 planned · China
  14. Jun 4, 2026Phase 3 study in Resectable Gastric/Gastroesophageal Junction AdenocarcinomaNCT07643623 · 720 planned · China
  15. Oct 19, 2026Phase 3 study in Locally Advanced Rectal CancerNCT07917468 · 500 planned · China

Ahead

  1. Mar 25, 2030Primary completion: phase 3 study in Locally Advanced Rectal CancerNCT07917468
  2. Jun 30, 2030Primary completion: phase 2 study in CLDN18.2 PositiveNCT07483567
  3. Dec 31, 2031Primary completion: phase 3 study in Resectable Gastric/Gastroesophageal Junction AdenocarcinomaNCT07643623

TargetBeta

PDCD1 →read by rule
“A recombinant human monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1; PDCD1; PD1), ”NCIt, by rule
“Programmed cell death protein 1 antagonist”ChEMBL 37, by rule

Other programs on PDCD1

ProgramCompanyFurthest phaseStudies
ivonescimabruleAkesophase 348
rilvegostomigAstraZenecaphase 324
Iparomlimab/TuvonralimabruleQilu Pharmaceuticalphase 322
volrustomigAstraZenecaphase 319
tivunatamigPfizerphase 315
nilvanstomigruleSuzhou Zelgen Biopharmaceuticalsphase 315
pucotenlimabruletaizhou-hanzhong-biomedical-co-ltdphase 315
enlonstobartruleCSPC Pharmaceutical Groupphase 315
ezabenlimabBoehringer Ingelheimphase 313
Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363ruleInnovent Biologicsphase 310
rulonilimabruleLunan Pharmaceutical Groupphase 39
Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868Sino Biopharmaceuticalphase 34

Studies

All 29 Innovent Biologics leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07917468Locally Advanced Rectal Cancer · China3Not yet recruitingMar 25, 2030500
NCT07643623Resectable Gastric/Gastroesophageal Junction Adenocarcinoma · China3RecruitingDec 31, 2031720
NCT07483567CLDN18.2 Positive · China2RecruitingJun 30, 203090
NCT05849246Non-squamous Non-small-cell Lung Cancer · China2TerminatedNov 30, 20234
NCT05572463Melanoma · United States, Australia, France and more2WithdrawnJun 30, 20270
NCT05337267Healthy Male Subjects · China1CompletedMay 24, 2023117
NCT05280626Lymphoma, Large B-Cell, Diffuse2Not yet recruitingDec 31, 2025100
NCT05119998Solid Tumor · China1CompletedJul 27, 202348
NCT05116462Carcinoma, Non-Small-Cell Lung · China3Active, not recruitingSep 30, 2026506
NCT05039658DLBCL · China1UNKNOWNJul 12, 202250
NCT04675983Gastric Adenocarcinoma · China3TerminatedFeb 12, 202336
NCT04427774Advanced or Metastatic Solid Tumors · China1TerminatedFeb 8, 20218
NCT04401813Advanced Hepatocellular Carcinoma · China1CompletedJun 21, 202497
NCT04353830Advanced Malignancies · China1CompletedMay 11, 202234
NCT04277663Acral Melanoma That Has Been Removed by Surgery · China3TerminatedFeb 28, 2023136
NCT04258111Colorectal Neoplasms · China2TerminatedOct 26, 20204
NCT04177290Carcinoma, Non-Small-Cell Lung · China1CompletedFeb 28, 202148
NCT04085185Advanced Malignancies · China1UNKNOWNDec 15, 2023268
NCT04044222Classic Hodgkin's Lymphoma · China3UNKNOWNJul 30, 2023240
NCT03802240Non-Squamous Non-Small Cell Lung Cancer · China3CompletedJul 31, 2021492
NCT03745170Stomach Neoplasms · China3CompletedJun 20, 2021650
NCT03748134Esophageal Squamous Cell Carcinoma · United States, Australia, Belgium and more3CompletedSep 9, 2021746
NCT03629925Squamous NSCLC · China3CompletedMar 25, 2020357
NCT03607539Lung Neoplasms · China3CompletedNov 15, 2019397
NCT03568539Advanced/Metastatic Solid Malignancies · United States1CompletedNov 9, 202039
NCT03228836Effect of Drugs · China2CompletedFeb 28, 202028
NCT03150875Carcinoma, Non-Small-Cell Lung · China3CompletedFeb 22, 2023290
NCT03116152Esophageal Squamous Cell Carcinoma · China2CompletedOct 2, 2019190
NCT02937116Neoplasms · China1CompletedSep 30, 2020233

How it is read

Names in the registry

  • “Sintilimab”, 15 entries
  • “IBI308”, 5 entries
  • “IBI939+ Sintilimab”, 2 entries
  • “IBI110+ Sintilimab”, 2 entries
  • “fruquintinib+sintilimab”, 1 entry

Codes read as this program: IBI308.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.